Lilly Sells the Same Drug at $1,086 and $299. The Gap Is the Strategy.

There is a single molecule called tirzepatide. Eli Lilly will sell you a 28-day supply of it for $1,086.37 if you go through your insurance.² It will also sell you the same active drug, in a single-dose vial, for as little as $299 a month if you pay cash through its own website.⁴ Same compound, same company, same factory - and a price gap of nearly four to one. That gap is not an accident, a glitch, or a charity. It is the strategy, drawn in dollars.

The official story is that the high price is greed and the low price is a concession Lilly was pressured into making for access. The real story runs the other way. The $1,086 list price is the lever Lilly pulls inside the insurance system, and the $299 cash price is a weapon it built to win a market - by starving out competitors and getting in front of the government before the government gets to it.

The list price was never the price anyone pays

When Zepbound was approved in November 2023, Lilly set the list price at $1,059.87 and said it was about 20% below the leading semaglutide injection.¹ Both of those numbers are marketing artifacts. The list price - what the industry calls wholesale acquisition cost - is the figure Lilly charges wholesalers before any rebate or discount, and Lilly says so plainly.² In the insurance channel, pharmacy benefit managers negotiate large rebates off that headline number. A high sticker price isn't a bug in that system; it's the raw material. The bigger the list price, the bigger the rebate a PBM can extract and show its clients - which is exactly why the list price is set high and held there even as the drug gets cheaper to everyone in practice.

You can see the gap between sticker and reality in Lilly's own filings. In 2025, Mounjaro and Zepbound together made up 56% of the company's total revenue, with Zepbound alone up about 175% year over year to $13.5 billion.³ And yet the same 10-K states that U.S. volume growth was partially offset by lower realized prices in both products across every quarter of the year.³ The list price barely moved. The price Lilly actually banks per patient was falling. The company is selling far more boxes for less money each - which is the signature of a business chasing share, not margin.

The $299 channel is a moat, not a mercy

On December 1, 2025, Lilly cut the cash price of Zepbound single-dose vials sold through LillyDirect to $299-$449 a month, down from $349-$499, and explicitly described the move as bypassing third-party supply-chain entities.⁴ Read that as a charity and you miss what it does. Look at the timing instead. By the time Lilly cut the cash price, the cheap alternative had been removed. After the FDA declared the tirzepatide shortage resolved in December 2024, and a federal court in Texas denied the compounders' bid to keep going in early 2025, the enforcement discretion that let pharmacies sell compounded copies ended - first for retail-style 503A pharmacies, then for the larger 503B outsourcing facilities on March 19, 2025.⁷ The grey market that had been undercutting Zepbound on price was shut by law.

Compounders had been the real competition for the cash-paying, uninsured patient - the one who couldn't get a PBM rebate. The moment that channel was legally closed, Lilly's own direct-to-consumer vials moved into the vacuum, and at a price the compounders used to occupy. It worked: direct-to-consumer sales then accounted for more than a third of new Zepbound prescriptions.⁴ Lilly didn't just lower a price. It rebuilt the bottom of the market in its own image and collected the patients who used to buy from somebody else.

Getting in front of the government before it arrives

The third front is the one that matters most over a decade. Medicare's Part D program has long excluded drugs prescribed primarily for weight loss, and at the state level the picture is just as thin - only 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of early 2026, and even then usually behind prior authorization.⁶ That left a vast, government-paid population that Lilly's drug could not legally reach. Rather than wait to be compelled, Lilly negotiated. It reached preliminary pricing agreements with the U.S. government in 2025, and from July 1, 2026, eligible Medicare Part D patients can get the Zepbound KwikPen for weight loss at $50 a month through what Lilly calls its Medicare GLP-1 Bridge program.⁵

A $50 Medicare price looks like surrender. It is closer to a down payment. By walking into the government channel on its own terms - a defined program, a defined price, a defined eligible population - Lilly sets the reference point before a future round of mandatory price negotiation can set one for it. The same logic shows up in its next product: when the FDA approved Lilly's oral GLP-1 pill in April 2026, it arrived at $149 a month for self-pay and $25 for the commercially insured with a savings card.⁸ The pattern is consistent. Establish the volume, establish the price points, and own the field before the rules change underneath you.

The honest counter: maybe access just won

The fair objection is that this reads too cynically. Lilly's own numbers say realized prices fell while volume soared, which is exactly what you'd expect if competition and public pressure were genuinely forcing prices down toward patients' reach.³ A $50 Medicare price and a $299 cash vial are real money in real pockets, whatever the boardroom motive. And the compounding shutdown was a court and an agency acting on a resolved shortage, not a favor Lilly engineered.⁷ All true. But intent and outcome aren't in tension here - they're aligned, which is the point. The most durable strategies are the ones where doing the self-interested thing and the popular thing are the same move. Lilly lowered prices because lower prices, run through the right channels at the right moment, win more than they cost. Access advocates and Lilly's strategists ended up wanting the same thing for very different reasons, and only one of them is keeping the patients.

So the real product was never the molecule, which anyone can now copy once the patent clock runs out. The product is the architecture: a high list price that feeds the rebate machine, a cash channel priced to inherit the grey market the day it was outlawed, and a government deal struck early enough to set the reference point rather than receive it. Lilly didn't lower the price of tirzepatide. It built three doors into one drug and made sure it owned all three. The genius isn't the $299. It's that the $299 arrived exactly when there was nowhere cheaper left to go.